Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).
Johnathan K JoffeFay H CaffertyLaura MurphyGordon J S RustinSyed A SohaibRhian GabeSally P StenningElizabeth C JamesDipa NoorSimona WadeFrancesca SchiavoneSarah SwiftElaine DunwoodieMarcia HallAnand SharmaJeremy P BraybrookeJonathan ShamashJohn LogueHenry H TaylorIvo HennigJeff WhiteSarah RudmanJane WorldingDavid J BloomfieldGuy FaustHilary GlenRachel JonesMichael J SecklGraham MacDonaldThiagarajan SreenivasanSatish KumarAndrew S ProtheroeRamachandran VenkitaramanDanish MazharVictoria CoyleMartin HighleyTom GeldartRobert LaingRichard S KaplanRobert A Huddartnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Surveillance is a safe management approach-advanced relapse is rare, salvage treatment successful, and outcomes excellent, regardless of imaging frequency or modality. MRI can be recommended to reduce irradiation; and no adverse impact on long-term outcomes was seen with a reduced schedule.
Keyphrases
- phase iii
- open label
- clinical trial
- high resolution
- public health
- phase ii
- magnetic resonance imaging
- double blind
- papillary thyroid
- germ cell
- study protocol
- randomized controlled trial
- emergency department
- placebo controlled
- squamous cell carcinoma
- contrast enhanced
- free survival
- metabolic syndrome
- lymph node metastasis
- skeletal muscle
- mass spectrometry
- young adults
- photodynamic therapy